Table 6 Secondary analysis 4: safety and tolerability of neo-adjuvant rituximab
Severity/grade | Adverse events (n) | Possible, probable, or definite attribution (n) | Description of related adverse events (n of patients affected) |
|---|---|---|---|
Mild/1 | 6 | 2 | Fatigue (×2) |
Moderate/2 | 3 | 2 | Infusion related reaction (×2) |
Severe/3 | 0 | 0 | Â |
Life-threatening/4 | 1 | 0 | Â |
Fatal/5 | 0 | 0 | Â |
Total | 10 | 4 | Â |